Payment overview · 2025
General Payments
$137.56
6 reported records · 6 companies
Healthcare provider profile · identity verified
Guilda Monfort Saint-Fleur, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SEBRING, FL · NPI 1639490782
Verified facts
What the public records show
CMS Open Payments records show Guilda Monfort Saint-Fleur, MD received $137.56 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.64 | 23.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.90 | 18.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.44 | 17.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.62 | 17.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.85 | 13.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.11 | 11.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.56 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 43 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
124 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 469 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 115 |
| Losartan Potassium | Losartan Potassium | 262 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 96 |
| Alprazolam | Alprazolam | 261 | 64 |
| Lisinopril | Lisinopril | 253 | 83 |
| Gabapentin | Gabapentin | 217 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 52 |
| Famotidine | Famotidine | 160 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 159 | 34 |
| Montelukast Sodium | Montelukast Sodium | 154 | 60 |
| Omeprazole | Omeprazole | 154 | 48 |
| Carvedilol | Carvedilol | 147 | 42 |
| Temazepam | Temazepam | 142 | 35 |
| Trazodone Hcl | Trazodone Hcl | 139 | 51 |
| Azithromycin | Azithromycin | 135 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 40 |
| Sertraline Hcl | Sertraline Hcl | 128 | 45 |
| Mounjaro | Tirzepatide | 124 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 36 |
| Ozempic | Semaglutide | 104 | 27 |
| Tramadol Hcl | Tramadol Hcl | 99 | 35 |
| Metformin Hcl | Metformin Hcl | 95 | 30 |
| Ezetimibe | Ezetimibe | 94 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 27 |
| Simvastatin | Simvastatin | 89 | 29 |
| Metformin Hcl Er | Metformin Hcl | 85 | 27 |
| Glipizide Er | Glipizide | 80 | 24 |
| Methylprednisolone | Methylprednisolone | 79 | 72 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 58 |
| Alendronate Sodium | Alendronate Sodium | 77 | 25 |
| Potassium Chloride | Potassium Chloride | 76 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 26 |
| Clonidine Hcl | Clonidine Hcl | 74 | 22 |
| Furosemide | Furosemide | 73 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 47 |
| Allopurinol | Allopurinol | 62 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 16 |
| Meloxicam | Meloxicam | 60 | 24 |
| Pregabalin | Pregabalin | 60 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 17 |
| Eliquis | Apixaban | 58 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 51 |
| Glimepiride | Glimepiride | 56 | 18 |
| Lorazepam | Lorazepam | 56 | 14 |
| Atenolol | Atenolol | 52 | 17 |
| Fenofibrate | Fenofibrate | 51 | 18 |
| Ondansetron Odt | Ondansetron | 50 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 38 |
| Bupropion Xl | Bupropion Hcl | 48 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 20 |
| Nifedipine Er | Nifedipine | 47 | 17 |
| Spironolactone | Spironolactone | 47 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 19 |
| Xarelto | Rivaroxaban | 46 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Linzess | Linaclotide | 43 | 18 |
| Celecoxib | Celecoxib | 42 | 17 |
| Estradiol | Estradiol | 42 | 17 |
| Jardiance | Empagliflozin | 42 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 16 |
| Glipizide | Glipizide | 39 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Trulicity | Dulaglutide | 36 | 12 |
| Azelastine Hcl | Azelastine Hcl | 35 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Fluconazole | Fluconazole | 32 | 20 |
| Buspirone Hcl | Buspirone Hcl | 31 | 15 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Baclofen | Baclofen | 30 | 14 |
| Meclizine Hcl | Meclizine Hcl | 30 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Prednisone | Prednisone | 27 | 20 |
| Cephalexin | Cephalexin | 25 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 13 |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | 11 |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.56 · 6 records | ABBVIE INC. | CONTRAVE, CREON, FREESTYLE LIBRE 3, LINZESS, MOUNJARO, OTEZLA, REPATHA, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error